Skip to content

Feasibility of WB-EMS in Frail Older People

Feasibility and Safety of Whole-Body Electromyostimulation (WB-EMS) in Frail Older People: A Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04495647
Enrollment
30
Registered
2020-08-03
Start date
2020-07-22
Completion date
2021-02-28
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty, Mobility Limitation

Brief summary

Exercise in general and resistance training (RT) in particular have demonstrated positive effects on physical functioning and frailty. However, frail older people with functional impairments are among the least physically active and may have problems reaching high intensity levels. The use of special vests with integrated electrodes allows the simultaneous innervation of all large muscle groups by external electrical stimulation, inducing a high-intensity RT at low subjective effort level. This whole-body electromyostimulation (WB-EMS) may be a feasible option inducing training stimuli for functionally impaired frail older people. This study aims at investigating the feasibility and safety of WB-EMS in frail older people with functional limitations. To explore the effects of age and functional status, young and robust old reference groups will serve as comparators.

Interventions

Whole-Body Electromyostimulation (WB-EMS): Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied. After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 4 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping and lower extremity strength/power will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)). WB-EMS will be fully supervised one on one. All three arms will receive the same intervention.

Sponsors

Paracelsus Medical University
CollaboratorOTHER
University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

frail older people (n=10) pre-post; robust older (n=10) and young (n=10) reference groups with identical intervention

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Frail people Inclusion Criteria: * 75+ years * Frail * able to walk 4m w/o walking aid * no prior WB-EMS exposure

Exclusion criteria

* severe visual or hearing impairments * major cognitive impairment (MMSE \<10) * medications with muscle-anabolic effects * medical conditions affecting trainability of muscles (e.g. Myasthenia gravis, Cushing syndrome, Morbus McArdle) * surgery within past two months * history of rhabdomyolysis * medical conditions affecting sensation of electrical stimuli (e.g. severe polyneuropathy) * severe renal insufficiency (eGFR\<30 ml/min/1.73m²) * electronic implants * acute or untreated abdominal wall or inguinal hernia Robust people Inclusion Criteria: * 75+ years * Robust * no prior WB-EMS exposure

Design outcomes

Primary

MeasureTime frameDescription
Recruitment rate8 weeksmeasured by ratio of included/eligible participants
estimated glomerular filtration rate (eGFR)measured at baseline to week 1, week 3 and week 8eGFR (creatinine clearance) measured in mL/min/1.73m² before, 48, 72 hours after training
Concentration of Creatinkinase (CK)measured at baseline to week 1, week 3 and week 8Concentration of CK measured in U/l before, 48, 72 hours after training
Concentration of Myoglobin (MB)measured at baseline to week 1, week 3 and week 8Concentration of MB measured in µg/l 3 hours after training
Intervention engagement measured by the Hopkins Rehabilitation Engagement Scale (HRERS)at 8 weeksThe HRERS, reported by instructors, comprises of 5 items on a verbal rating scale from 'Never' to 'Always'. Higher scores reflect greater levels of engagement.
Perceived enjoyment measured by the Physical Activity Enjoyment Scale for Older Adults (PACES-8)Change from baseline to 8 weeksThe PACES-8 comprises of 8 items on a 7-point bipolar rating scale. A sum score is calculated with higher PACES scores reflecting greater levels of enjoyment.
Dropout ratefrom baseline to 8 weeksmeasured by the proportion of participants not completing the study
Retention rateat 8 weeksmeasured by proportion of participants remaining in the study
Compliancefrom baseline to 8 weeksmeasured by proportion of attended training sessions

Secondary

MeasureTime frameDescription
Skeletal muscle massChange from baseline to 8 weeksBioelectrical impedance analysis (BIA)
Mobility measured by the Timed up & go test (TUG)Change from baseline to 9 weeksThe TUG requires the participants to stand up from chair, walk at usual pace to line at 3m, turn, walk back and sit down again. The time in seconds is recorded.
Maximum knee/hip extension strengthChange from baseline to 9 weeksIsokinetic leg press in Newton
Rate of persons with Albuminuriameasured at baseline to week 1, week 3 and week 8Rate of persons with Albuminuria ≥ 2+ measured with a semi quantitative urine dipstick 24 hours after training
Rate of persons with Proteinuriameasured at baseline to week 1, week 3 and week 8Rate of persons with Proteinuria ≥ 3+ measured with a semi quantitative urine dipstick 24 hours after training
Concentration of Ureameasured at baseline to week 1, week 3 and week 8Concentration of Urea measured in mg/dl before, 48, 72 hours after training
Concentration of Cystatin Cmeasured at baseline to week 1, week 3 and week 8Concentration of Cystatin C measured in mg/l before, 48, 72 hours after training
Concentration of Creatininemeasured at baseline to week 1, week 3 and week 8Concentration of Creatinine measured in mg/dl before, 48, 72 hours after training
Concentration of Sodiummeasured at baseline to week 1, week 3 and week 8Concentration of Sodium measured in mmol/l before, 48, 72 hours after training
Concentration of Potassiummeasured at baseline to week 1, week 3 and week 8Concentration of Potassium measured in mmol/l before, 48, 72 hours after training
Concentration of Calciummeasured at baseline to week 1, week 3 and week 8Concentration of Calcium measured in mmol/l before, 48, 72 hours after training
Concentration of Phosphatemeasured at baseline to week 1, week 3 and week 8Concentration of Phosphate measured in mmol/l before, 48, 72 hours after training
Rhabdomyolysis surveillance measured by a self-developed questionnairemeasured weeklyThe questionnaire is to be filled out before, immediately after and 24 hours following training and containing information on specific (dark urine, muscle weakness, muscle pain) and unspecific (tachycardia, fever, general malaise, nausea, vomiting) symptoms and other adverse events (e.g. falls)
Pain assessed by the Brief Pain Inventory (BPI-SF)measured at baseline to week 1, week 3 and week 8The BPI-SF comprises of 15 items asking questions on pain location, severity and interference and scored from 0 to 10 with higher scores indicating worse outcomes.
Fatigue assessed by the Brief Fatigue Inventory (BFI)measured at baseline to week 1, week 3 and week 8The BFI comprises of 10 items asking questions on fatigue severity and interference and scored from 0 to 10 with higher scores indicating worse outcomes.
System usability measured by the System Usability Scale (SUS)once at 8 weeksThe SUS, reported by instructors, comprises of 10 items on a 5-point Likert scale from 1 ('strongly disagree') to 5 ('strongly agree'). Higher scores reflect greater levels of usability.
Lower extremity functioning measured by the Short Physical Performance Battery (SPPB)Change from baseline to 9 weeksThe SPPB comprises of three dimensions, balance (static - standing in 3 positions of increasing difficulty by reducing base of support for max. 10s), gait (usual pace - two walks of 4m lengths), functional strength (chair rise - five times sit-to-stand transfers as fast as possible). A sum score is calculated (0-12 points) with higher scores indicating better functional status and each dimension being equally weighed (0-4 points).

Other

MeasureTime frameDescription
Concentration of high-sensitive cardiac troponin T (hs-cTnT)measured at baseline to week 1, week 3 and week 8Concentration of hs-cTnT measured in ng/ml before, 48, 72 hours after training
Concentration of N-terminal pro b-type natriuretic peptide (NT-proBNP)measured at baseline to week 1, week 3 and week 8Concentration of NT-proBNP measured in pg/ml before, 48, 72 hours after training
Concentration of Triglyceridesmeasured at baseline and week 8Concentration of Triglycerides measured in mg/dl before first and last trainings
Concentration of high-density lipoprotein (HDL)measured at baseline and week 8Concentration of HDL measured in mg/dl before first and last trainings
Concentration of low-density lipoprotein (LDL)measured at baseline and week 8Concentration of LDL measured in mg/dl before first and last trainings
Concentration of Cholesterinmeasured at baseline and week 8Concentration of Cholesterin measured in mg/dl before first and last trainings
Concentration of High-sensitivity C-reactive protein (hs CRP)measured at baseline to week 1, week 3 and week 8Concentration of hs CRP measured in mg/l before, 48, 72 hours after training
Concentration of Interleukin 6 (IL-6)measured at baseline to week 1, week 3 and week 8Concentration of IL-6 measured in ng/l before, 3h, 48, 72 hours after training
Health-related quality of life measured by the patient-reported Health Survey Short Form (SF-12)Change from baseline to 9 weeksThe SF-12 comprises of 12 items weighted and summed to provide physical and mental health scores (PCS and MCS), ranging from 0 to 100 with higher scores reflecting greater levels of the respective construct.
Concentration of Creatinkinase Muscle/Brain (CK-MB (CK-2))measured at baseline to week 1, week 3 and week 8Concentration of CK-MB (CK-2) measured in ng/ml before, 48, 72 hours after training
Concentration of Glucosemeasured at baseline and week 8Concentration of Glucose measured in mg/dl before first and last trainings

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026